You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Response to ‘Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors’
  1. Darryl Leong1,
  2. Christopher Hillis2,
  3. Nazanin Aghel3,
  4. Gregory Pond2,
  5. Hsien Seow2
  1. 1 Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
  2. 2 Department of Oncology, McMaster University, Hamilton, Ontario, Canada
  3. 3 Department of Medicine, McMaster University, Hamilton, Ontario, Canada
  1. Correspondence to Dr Darryl Leong, Population Health Research Institute, McMaster University, Hamilton L8L 2X2, Ontario, Canada; leongd{at}phri.ca

https://doi.org/10.1136/heartjnl-2021-319415

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The Authors’ reply

    We read with interest the correspondence by Papaila et al 1 concerning our work on cardiovascular outcomes among patients with chronic myeloid leukaemia (CML). They raise several important points. We agree that the characteristics of patients prescribed tyrosine kinase inhibitors (TKI) are likely to have evolved since the introduction of these transformative therapies. In our research, we found that prior to the regulatory approval of TKI, the incidence of adverse cardiovascular events among patients with CML was lower than among age-matched and …

    View Full Text

    Footnotes

    • Twitter @DarrylLeong

    • Contributors All authors have contributed to the content of this letter.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles